Literature DB >> 20406933

Randomized phase II trials: inevitable or inadvisable?

Hui K Gan1, Axel Grothey, Gregory R Pond, Malcolm J Moore, Lillian L Siu, Daniel Sargent.   

Abstract

Mesh：

Year:  2010        PMID： 20406933     DOI： 10.1200/JCO.2009.26.3343

Source DB:  PubMed          Journal:  J Clin Oncol        ISSN： 0732-183X            Impact factor:   44.544


× No keyword cloud information.
  26 in total

1.  Tumor status at 12 weeks predicts survival in advanced colorectal cancer: findings from NCCTG N9741.

Authors:  James M Heun; Axel Grothey; Megan E Branda; Richard M Goldberg; Daniel J Sargent
Journal:  Oncologist       Date:  2011-05-31

2.  Shortcomings in the clinical evaluation of new drugs: acute myeloid leukemia as paradigm.

Authors:  Roland B Walter; Frederick R Appelbaum; Martin S Tallman; Noel S Weiss; Richard A Larson; Elihu H Estey
Journal:  Blood       Date:  2010-06-10       Impact factor: 22.113

3.  Resampling phase III data to assess phase II trial designs and endpoints.

Authors:  Manish R Sharma; Theodore G Karrison; Yuyan Jin; Robert R Bies; Michael L Maitland; Walter M Stadler; Mark J Ratain
Journal:  Clin Cancer Res       Date:  2012-01-27       Impact factor: 12.531

4.  More randomization in phase II trials: necessary but not sufficient.

Authors:  Lawrence Rubinstein; Michael Leblanc; Malcolm A Smith
Journal:  J Natl Cancer Inst       Date:  2011-06-27       Impact factor: 13.506

Review 5.  Randomized phase II trials: a long-term investment with promising returns.

Authors:  Manish R Sharma; Walter M Stadler; Mark J Ratain
Journal:  J Natl Cancer Inst       Date:  2011-06-27       Impact factor: 13.506

6.  Latest developments in the treatment of melanoma: 'a penicillin moment for cancer'?

Authors:  Spyros Retsas
Journal:  J R Soc Med       Date:  2011-06       Impact factor: 5.344

7.  Design and Evaluation of an External Control Arm Using Prior Clinical Trials and Real-World Data.

Authors:  Steffen Ventz; Albert Lai; Timothy F Cloughesy; Patrick Y Wen; Lorenzo Trippa; Brian M Alexander
Journal:  Clin Cancer Res       Date:  2019-06-07       Impact factor: 12.531

8.  To randomize, or not to randomize, that is the question: using data from prior clinical trials to guide future designs.

Authors:  Alyssa M Vanderbeek; Steffen Ventz; Rifaquat Rahman; Geoffrey Fell; Timothy F Cloughesy; Patrick Y Wen; Lorenzo Trippa; Brian M Alexander
Journal:  Neuro Oncol       Date:  2019-10-09       Impact factor: 12.300

Review 9.  Precision medicine needs randomized clinical trials.

Authors:  Everardo D Saad; Xavier Paoletti; Tomasz Burzykowski; Marc Buyse
Journal:  Nat Rev Clin Oncol       Date:  2017-02-07       Impact factor: 66.675

10.  New considerations in the design of clinical trials for the treatment of acute leukemia.

Authors:  Christopher S Hourigan; Judith E Karp
Journal:  Clin Investig (Lond)       Date:  2011-04-01
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.